|
After Adderall, what's next for Shire? CEO Matthew Emmens thinks the answer lies in a simple strategy.
Jul 1, 2004
By:
Joanna Breitstein
After Adderall, what's next for Shire? CEO Matthew Emmens thinks the answer lies in a simple strategy.
|
|
Marketers spent the last 10 years learning how to advertise to consumers -- the next 10 will be about integrating those efforts.
Jun 1, 2004
By:
Joanna Breitstein
Orchestra conductors may, at first, seem like an unlikely comparison for pharma marketers. After all, a conductor's job is to ensure that each instrument harmonizes with others within the section; that all the sections complement one another; and that the timing, tone, and pitch of each disparate part are flawlessly executed. But when one appreciates the challenges facing executives today in integrating all components into the marketing mix, the analogy seems appropriate.
|
|
Science is beginning to understand the role of insulin resistance. Now it's industry's turn to draw the blueprints for the biggest market yet.
Jan 1, 2004
By:
Joanna Breitstein
Think back: When did you first hear the phrase metabolic syndrome? When did it start to become part of your business and its plans?
|
A PE Roundtable
Sep 1, 2003
By:
Joanna Breitstein
Pharmaceutical Executive challenges 21 experts to grapple with the future of the healthcare system.
|
Yamanouchi Pharma America Expects Its First Approval
Jul 1, 2003
By:
Joanna Breitstein
Paramus Road in New Jersey is a construction zone, filled with cars edging their way past lots slated for shopping plazas, food joints, and industrial office parks. Along that thoroughfare-near small pharma companies like Faulding and Synaptic and just a few miles away from Roche-lies Yama-nouchi Pharma America (YPA). Like the environment unfolding around it, YPA is in the process of becoming.
|
Catherine Sohn Guides GSK's Consumer Powerhouse
Apr 1, 2003
By:
Joanna Breitstein
In hindsight, it seems Catherine Angell Sohn, PharmD, was destined to become vice-president, worldwide business development for GlaxoSmithKline Consumer Healthcare (GSKCH). Sohn, a former pharmacist, architect of three Rx blockbuster launches, and engineer of innumerable partnerships and licensing agreements, is a pivotal link between GSK's pharmaceuticals and consumer healthcare.
|
DIA Remains Committed to Quality, Individuals
Mar 1, 2003
By:
Joanna Breitstein
All is quiet at the Drug Information Association's new headquarters, a short ride from the hubbub of Philadelphia. But inside, the association buzzes with change as it harnesses the expertise and energy of its members to improve healthcare around the world. Now approaching its 40th year, DIA is expanding both its educational programs and its global reach.
|
Feb 1, 2003
By:
Joanna Breitstein
Abuse of Purdue Pharma's chronic pain treatment OxyContin (oxycodone), a class II narcotic analgesic, began to receive intense media scrutiny in early 2001. Teenagers and young adults had begun abusing the medication, and the consumer media jumped in to cover this new "drug de jour," calling it the next crack cocaine because of its potential for addiction. But patients, many of them suffering from cancer, say it's heaven-sent and the only medication that provides them with continual pain relief. Here, Michael Friedman, Purdue's executive vice-president and COO, describes the balancing act his company must maintain to combat OxyContin abuse without restricting patient access.
|
Nov 1, 2002
By:
Joanna Breitstein
The newest study released by the Association of Medical Publishers (AMP) suggests that pharma companies could improve their return on investment by taking a more mathematical approach to determining the marketing mix.
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
